University of Münster

Scipharm Sarl

Xaver Koenig

Michael Freissmuth

Marko Mihovilovic

Karlheinz Hilber

Michael Schnuerch

Christina Gloeckel

Simon Keuerleber

Moumita Koley

Thomas Linder

Christina Just

Agnes Mike

The present invention provides compositions comprising a prostacyclin or prostacyclin analog, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analog for treating or preventing a condition associated with cystic fibrosis in a subject.

Composition for the treatment of cystic fibrosis

A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (I), wherein X is independently &#x2014;NR&#x2014;or &#x2014;O&#x2014;, Ris hydrogen or C-alkyl; Ris hydroxy, C-alkyl, C-alkoxy, carboxy, C-alkoxycarbonyl, halo, cyano, nitro, formyl, amino, C-alkylamino, or di-C-alkylamino, the C-alkyl or -alkoxy residue being optionally substituted with one or more Rsubstituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; Ris hydrogen, aryl, heteroaryl, or C-alkyl, the aryl or heteroaryl residue being optionally substituted with one or more Rsubstituents, and where the C-alkyl is optionally further substituted with one or more Rsubstituents; and Ris selected from hydrogen, halo, NRR, OR, SR, and R, where the same options apply for Ras for R; with the proviso that the compound of formula (I) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.

Triazine derivatives as differentiation catalysts

The present invention provides a composition comprising at least one prostacyclin or prostacyclin analog or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4 inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.

Provided are compounds of formula (I) and/or salts thereof, of the class of substituted pyridines and pyrimidines, useful for inducing cardiomyogenesis, a process for producing cardiomyocyte-like cells from mammalian cells by culturing mammalian cells in the presence of the compound of formula (I), the pharmaceutical use of compounds of formula (I) for producing cardiomyocyte-like cells from omnipotent, pluripotent, or lineage committed mammalian cells, and the use of thus produced cardiomyocyte-like cells for treating disorders associated with impaired function of the heart.

Substituted pyridines and pyrimidines

Growing community of inventors

Moedling, Austria

Xaver Koenig